Investors
Investing in
Constructive.Bio
Unlocking Tomorrow's Possibilities: Pioneering the Next Era of Genetic Technology and Synthesis
Our CEO
[ 01 ] Our technologies are catalysts, transforming industries and unlocking opportunities invalue creation
Ola Wlodek
Constructive Bio, CEO
Our Investors
[ 01 ] Ahren is an investment institution that supports transformational companies at the intersection of deep tech and deep science that will penetrate, or create, massive markets.
Ahren believes in taking asymmetric, considered, risk that will deliver superior rewards - capturing a generational opportunity to provide smart capital to deep technology.
[ 02 ] OMX Ventures is a VC firm investing in early-stage companies building tools and instrumentation for life sciences, and novel platforms for therapeutics.
It was founded upon the simple idea that in this new Century of Biology, scientists and engineers will radically remake the future of medicine through the use of better tools, big data and computing, and the forward application of biologic insights for the creation of new tools and technologies.
[ 03 ] As a multi-stage investor, Paladin’s core strength is identifying, supporting and investing in innovative companies that develop promising, early-stage technologies to address the critical cyber and advanced technological needs of both commercial and government customers.
Combining proven investment experience with deep expertise in global security, cyber technology and cutting-edge research, Paladin has invested in more than 70 companies since 2008 and has been a trusted partner to investors, entrepreneurs and governments for over two decades.
[ 04 ] Fine Structure Ventures is a venture capital fund that is committed to advancing innovation in science and technology.
From aerospace and biology to climate tech, quantum computing and the development of innovative materials, Fine Structure Ventures is tackling some of the most significant technological challenges we face today.
[ 05 ]
ND Capital is a venture capital firm that invests in disruptive technologies across sectors, stages, and technologies.
[ 06 ] Amadeus Capital Partners is a venture capital firm that invests in European high-technology companies.
Amadeus bring the know-how and networks to help entrepreneurs build great companies, from early stage to global growth.
[ 07 ] Jonathan Milner, Founder of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups.
Meltwind, Jonathan’s portfolio management team, focuses on Series A and B on platform technologies enabling drug discovery and development.
Our Vision in Numbers
Launched with a significant $15 million in seed investment to bring our ground breaking research to life and drive innovation.
Million Dollars
Market impact
Testimonials
With this investment, we aim to develop Constructive Bio’s technology to deliver biomanufacturing at scale. By providing a biological, cost-effective production process, we can help overcome shortfalls in global supplies of therapeutic peptides and proteins such as semaglutide.
Greg Winter
Ahren Science Partner and board member of Constructive Bio
It has been amazing to witness the evolution of Constructive Bio’s truly unique bioengineering and biomanufacturing platform technologies. We are honoured to be backing this impressive team as they move swiftly to realise the full potential of the technology with breakthrough medicines, enzymes and biomaterials in the future.
Paul Conley
Paladin Capital Group
Constructive Bio has cutting-edge technology with exceptional near- and long-term potential. It couples groundbreaking innovation with multiple distinct routes to market, and is set to revolutionise the sustainable biomanufacturing of new products across industries.
Shyam Kamadolli
Managing Director of Fine Structure Ventures
We are delighted to support Jason and the Constructive team in commercializing these breakthrough technologies. With highly valuable near-term applications and transformational potential across a wide range of industries in the medium term, we believe it is important to establish Constructive with the resources and tools to fully capture this value.
Matthew Newcombe-Ellis
Ahren Innovation Capital
By using AI and deep insight to enable the scalable and economical production of designed peptides and proteins containing non-canonical amino acids, Constructive Bio is building new drugs that will significantly improve patient outcomes. Constructive’s approach will also enable novel polymers such as high performant, biodegradable, and cost-effective plastics.
Craig Asher
OMX Ventures
Investment participation